Qu Biologics Appoints Former Novartis President Mr. Robert Pelzer to its Board of Directors

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 13, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, is pleased to welcome Mr. Robert Pelzer to the company's Board of Directors. Mr. Pelzer was most recently President of Novartis Corporation based in New York, NY.

"It is an honour to welcome Bob Pelzer, a distinguished and accomplished leader in the pharmaceutical industry, to Qu Biologics' Board of Directors," said Dr. Hal Gunn, CEO of Qu Biologics. "Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be invaluable to Qu Biologics during this important stage of our growth and development, as we advance our clinical trial in Crohn's disease and develop relationships with potential pharma partners," Dr. Gunn added.

For information about Qu Biologics' Crohn's disease clinical trial, visit www.qucrohnstrial.com.

For information about Qu Biologics and the science behind SSIs, visit www.qubiologics.com.

About Mr. Robert E. Pelzer

Mr. Robert E. Pelzer is an experienced leader with significant international experience. He was most recently President of Novartis Corporation. In that capacity, Mr. Pelzer was responsible for the Novartis Group Companies in the United States. Previously, Mr. Pelzer served as Global General Counsel and Head of Legal Services at Novartis Pharma AG, based in Basel, Switzerland. Prior to joining Novartis in 2002, Mr. Pelzer served as General Counsel and Senior Vice President at DuPont Pharmaceuticals. Mr. Pelzer has held a number of directorships including the leading industry association PhRMA, numerous Novartis subsidiaries, Idenix Pharmaceuticals and Litebook Company.

About Qu Biologics

Qu Biologics is a Vancouver-based private clinical stage biopharmaceutical company that develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.

Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics' forward-looking statements due to the risks and uncertainties inherent in Qu Biologics' business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.